14,500 Shares in Moderna, Inc. (NASDAQ:MRNA) Bought by Sassicaia Capital Advisers LLC

Sassicaia Capital Advisers LLC purchased a new stake in Moderna, Inc. (NASDAQ:MRNA - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 14,500 shares of the company's stock, valued at approximately $603,000. Moderna makes up 14.6% of Sassicaia Capital Advisers LLC's holdings, making the stock its 2nd biggest holding.

Other institutional investors and hedge funds have also modified their holdings of the company. Wilmington Savings Fund Society FSB grew its position in Moderna by 295.0% in the 4th quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company's stock worth $33,000 after purchasing an additional 587 shares during the last quarter. Compass Planning Associates Inc bought a new position in Moderna during the fourth quarter worth about $37,000. Venturi Wealth Management LLC boosted its holdings in Moderna by 286.2% during the fourth quarter. Venturi Wealth Management LLC now owns 896 shares of the company's stock valued at $37,000 after purchasing an additional 664 shares in the last quarter. Crowley Wealth Management Inc. acquired a new stake in Moderna in the 4th quarter valued at $41,000. Finally, MassMutual Private Wealth & Trust FSB lifted its holdings in shares of Moderna by 58.2% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company's stock valued at $44,000 after acquiring an additional 389 shares during the period. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms recently commented on MRNA. William Blair restated a "market perform" rating on shares of Moderna in a research report on Thursday, April 17th. Morgan Stanley reduced their price objective on Moderna from $39.00 to $32.00 and set an "equal weight" rating on the stock in a report on Wednesday, April 9th. Evercore ISI set a $50.00 price target on Moderna in a research note on Friday, February 14th. Leerink Partners dropped their price objective on Moderna from $31.00 to $27.00 and set an "underweight" rating for the company in a report on Thursday, January 16th. Finally, JPMorgan Chase & Co. lowered their price target on shares of Moderna from $40.00 to $33.00 and set an "underweight" rating for the company in a research report on Friday, March 21st. Four investment analysts have rated the stock with a sell rating, sixteen have given a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, Moderna has an average rating of "Hold" and a consensus price target of $58.70.

Moderna Trading Up 1.3 %

MRNA stock traded up $0.36 during mid-day trading on Tuesday, hitting $27.82. 5,238,914 shares of the company were exchanged, compared to its average volume of 7,367,871. The business has a 50 day simple moving average of $30.03 and a 200-day simple moving average of $38.15. The stock has a market capitalization of $10.76 billion, a PE ratio of -3.00 and a beta of 2.23. Moderna, Inc. has a 1-year low of $23.15 and a 1-year high of $170.47.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.